

Applicant, city and state	File No.	MM docket No.
A. Howard B. Dolgoff, Miramar Beach, Fl.	BPH-911223ME	93-178
B. Mark and Renee Carter, Miramar Beach, Fl.	BPH-911224MD	.....

2. Pursuant to section 309(e) of the Communications Act of 1934, as amended, the above applications have been designated for hearing in a consolidated proceeding upon the issues whose headings are set forth below. The text of each of these issues has been standardized and is set forth in its entirety under the corresponding headings at 51 Fed. Reg. 19347, May 29, 1986. The letter shown before each applicant's name, above, is used below to signify whether the issue in question applies to that particular applicant.

Issue Heading	Applicant(s)
1. Air Hazard .....	A
2. Comparative .....	A, B
3. Ultimate .....	A, B

3. If there is any non-standardized issue(s) in this proceeding, the full text of the issue and the applicant(s) to which it applies are set forth in an Appendix to this Notice. A copy of the complete HDO in this proceeding is available for inspection and copying during normal business hours in the FCC Dockets Branch (room 230), 1919 M Street, NW., Washington, DC. The complete text may also be purchased from the Commission's duplicating contractor, International Transcription Service, Inc. 2100 M Street, NW., suite 140, Washington, DC 20037; telephone (202) 857-3800.

Larry D. Eads,

Chief, Audio Services Division, Mass Media Bureau.

[FR Doc. 93-15527 Filed 6-30-93; 8:45 am]

BILLING CODE 6712-01-M

#### Renewal Application Designated for Hearing

1. The Commission has before it the following application for renewal of license:

Applicant, city and state	File No.	MM docket No.
A. Metrocomoc, Inc., Berlin, NH.	BR-901130XE	93-190

(Seeking a renewal of the license of Station WBRL(AM))

2. Pursuant to section 309(e) of the Communications Act of 1934, as amended, the above application has been designated for hearing in a proceeding upon whose issues are set forth below:

1. To determine whether Metrocomco, Inc. has the capability and intent to expeditiously resume broadcast operations of WBRL(AM) consistent with the Commission's Rules.

2. To determine whether Metrocomco, Inc. has violated §§ 73.1740 and/or 73.1750 of the Commission's Rules;

3. To determine, in light of the evidence adduced pursuant to the preceding issues, whether or not grant of the subject renewal of license application would serve the public interest, convenience and necessity.

A copy of the complete HDO in this proceeding is available for inspection and copying during normal business hours in the FCC Dockets Branch (Room 320), 1919 M Street, NW., Washington, DC. The complete text may also be purchased from the Commission's duplicating contractor, International Transcription Service, 2100 M Street, NW., suite 140, Washington, DC 20037 (telephone 202-857-3800).

Federal Communications Commission.

Larry D. Eads,

Chief, Audio Services Division, Mass Media Bureau.

[FR Doc. 93-15528 Filed 6-30-93; 8:45 am]

BILLING CODE 6712-01-M

#### Renewal Application Designated for Hearing

1. The Commission has before it the following application for renewal of license:

Applicant, city and state	File No.	MM docket No.
A. Stephen W. Yates, Lufkin, Texas.	BR-900402E6	93-189

(Seeking a renewal of the license of Station KSRK(AM))

2. Pursuant to section 309(e) of the Communications Act of 1934, as amended, the above application has been designated for hearing in a proceeding upon whose issues are set forth below:

1. To determine whether Stephen W. Yates has the capability and intent to expeditiously resume broadcast

operations of KSRK(AM) consistent with the Commission's Rules.

2. To determine whether Stephen W. Yates has violated Sections 73.1740 and/or 73.1750 of the Commission's Rules;

3. To determine, in light of the evidence adduced pursuant to the preceding issues, whether or not grant of the subject renewal of license application would serve the public interest, convenience and necessity.

A copy of the complete HDO in this proceeding is available for inspection and copying during normal business hours in the FCC Dockets Branch (room 320), 1919 M. Street, NW., Washington, DC. The complete text may also be purchased from the Commission's duplicating contractor, International Transcription Service, 2100 M Street, NW., suite 140, Washington, DC 20037 (telephone 202-857-3800).

Federal Communications Commission

Larry D. Eads

Chief, Audio Services Division, Mass Media Bureau.

[FR Doc. 93-15529 Filed 6-30-93; 8:45 am]

BILLING CODE 6712-01-M

#### FEDERAL TRADE COMMISSION

##### Granting of Request for Early Termination of the Waiting Period Under The Premerger Notification Rules

Section 7A of the Clayton Act, 5 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the Federal Register.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

## TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 060793 AND 061893

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
Southwestern Bell Corporation, Gustave M. Hauser, Montgomery Cablevision Limited Partnership	93-1073	06/07/93
Southwestern Bell Corporation, John D. Evans, Evanco, Inc	93-1074	06/07/93
George Soros, Falcon Drilling Company, Inc., Falcon Drilling Company, Inc	93-1094	06/07/93
Burlington Resources, Inc., Petrofina S.A., Fina Oil and Chemical Company	93-1097	06/07/93
Heywood Williams Group PLC, Beekman Settlement, LaSalle-Deitch Co., Inc	93-1108	06/07/93
Protective Life Corporation, Internationale Nederlanden Groep N.V., Wisconsin National Life Insurance Company	93-1111	06/07/93
Shamrock Holdings, Inc., Milton Maltz, Malrite Communications Group, Inc	93-1119	06/07/93
Trefoll Capital Investors, L.P., Roy E. Disney and Patricia A. Disney, Shamrock Holdings, Inc	93-1120	06/07/93
Roy E. Disney and Patricia A. Disney, Roy E. Disney and Patricia A. Disney, Big Country TV of Abilene, Inc	93-1121	06/07/93
Dort A. Cameron III, JWP Inc., JWP Information Services (East), Inc	93-1131	06/07/93
Ibrahim Morales, The Times Mirror Company, KDFW-TV, Inc. and KTBC-TV, Inc	93-1139	06/07/93
Anthony H. Reeves, The Olsten Corporation, The Olsten Corporation	93-1144	06/07/93
First Bank System, Inc., John J. Fauth, Republic Acceptance Corporation	93-1132	06/08/93
GATX Corporation, Westinghouse Electric Corporation, Westinghouse Electric Corporation	93-1149	06/08/93
D.D.I. Inc., First Mississippi Corporation, First Energy Corporation	93-1138	06/09/93
First American Capital, C.V., Commerce Clearing House, Inc., Facts on File, Inc	93-1103	06/10/93
Zions Bancorporation, Discount Corporation of New York, Discount Corporation of New York	93-1123	06/10/93
Acadia Partners, L.P., Major League Marketing, Inc., Major League Marketing, Inc	93-1134	06/10/93
International Semi-Tech Microelectronics, Inc., Semi-Tech (Global) Company Limited, The Singer Company N.V.	93-1145	06/10/93
Newell Co., PI Industries, Inc., PI Industries, Inc	93-1153	06/10/93
The Morgan Stanley Real Estate Fund, L.P., BankAmerica Corporation, BankAmerica Corporation	93-1078	06/11/93
Warburg, Pincus Investors, L.P., The News Corporation Limited, Benson Music Group, Inc	93-1150	06/11/93
The Prudential Insurance Co. of America, BraeLoch Holdings, Inc., BraeLoch Holdings, Inc	93-1152	06/11/93
Devon Energy Corporation, Petrofina S.A., Fina Oil and Chemical Company	93-1155	06/11/93
Fleming Companies, Inc., John A. Catsimatidis, Florida Supermarkets, Inc	93-1156	06/11/93
Savannah Foods & Industries, Inc., Ed Newbern, King Packaging Company, Inc	93-1164	06/11/93
Safeguard Scientifics, Inc., JWP Inc., Maris Equipment Company	93-1181	06/11/93
PepsiCo, Inc., Alpac Investments, Inc., Alpac Investments, Inc	93-1063	06/14/93
Cargill, Incorporated, Exxon Corporation, Exxon Corporation	93-1069	06/14/93
Whole Foods Market, Inc., Mrs. Gooch's Natural Food Markets, Inc., Mrs. Gooch's Natural FoodMarkets, Inc	93-1066	06/15/93
Sandra V. Gooch, Whole Foods Market, Inc., Whole Foods Market, Inc	93-1067	06/15/93
Pechiney, S.A., The Stroh Companies, Inc., The Stroh Brewery Company	93-1095	06/15/93
Danny O. Volland, Whole Foods Market, Inc., Whole Foods Market, Inc	93-1112	06/15/93
International Multifoods Corporation, Joseph A. Amicone, J. Amicone Company, Inc	93-1136	06/15/93
Geo. A. Hormel & Company d.b.a. Hormel Foods Corp., Reckitt & Colman plc, Reckitt & Colman Inc	93-1159	06/15/93
Banc One Corporation, Dennis Lochmandy, Prime Bank, c/o Premier Financial Corp	93-1167	06/15/93
United HealthCare Corporation, HMO America, Inc., HMO America, Inc	93-1173	06/15/93
Union Pacific Corporation, Parker & Parsley Petroleum Company, Dorchester Master Limited Partnership	93-1174	06/15/93
Warburg, Pincus Capital Company, L.P., Altresco Financial, Inc., Altresco Financial, Inc	93-1116	06/16/93
Leslie L. Dan, Hoechst Aktiengesellschaft, Granutec Inc	93-1133	06/16/93
Behr GmbH & Co., Behr America Holding, Inc., Behr America Holding, Inc	93-1083	06/17/93
AST Research Inc., Tandy Corporation, Tandy Corporation	93-1151	06/17/93
General Electric Company, GFC Financial Corporation, Verex Corporation	93-1158	06/17/93
George D. Behrakis, Glaxo Holdings, p.l.c., Glaxo, Inc. and Glaxo Group Ltd	93-1160	06/17/93
VEBA AG, Joseph H. Collie, Southchem, Inc	93-1161	06/17/93
Union Titanium Sponge Corporation, Tremont Corporation, Titanium Metals Corporation	93-1172	06/17/93

## FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay, or Renee A. Horton,  
Contact Representatives, Federal Trade  
Commission, Premerger Notification  
Office, Bureau of Competition, Room  
303, Washington, DC 20580, (202) 326-  
3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 93-15549 Filed 6-30-93; 8:45 am]

BILLING CODE 6750-01-M

[Dkt. C-3429]

**AE Clevite, Inc.; Prohibited Trade  
Practices, and Affirmation Corrective  
Actions**

**AGENCY:** Federal Trade Commission.

**ACTION:** Consent Order.

**SUMMARY:** In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent order prohibits, among other things, a Michigan manufacturer of locomotive engine bearings and its parent company, T&N PLC, from fixing prices or from inviting its competitors to fix or raise prices for locomotive engine bearings in

the future. The consent order requires AE Clevite and T&N to provide copies of the FTC complaint and consent order to the directors and officers of the company, subsidiaries, and divisions engaged in the design, manufacture, marketing or sale of locomotive engine bearings in the United States.

**DATES:** Complaint and Order issued June 8, 1993.<sup>1</sup>

**FOR FURTHER INFORMATION CONTACT:** Ronald Rowe, FTC/H-380, Washington, DC 20580. (202) 326-2610.

<sup>1</sup> Copies of the Complaint, the Decision and Order, and Commissioner Owen's statement are available from the Commission's Public Reference Branch, H-130, 6th Street & Pennsylvania Avenue, NW., Washington, DC 20580.

**SUPPLEMENTARY INFORMATION:** On Friday, April 2, 1993, there was published in the *Federal Register*, 58 FR 17405, a proposed consent agreement with analysis in the Matter of AE Clevite, Inc., for the purpose of soliciting public comment. Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to cease and desist, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45)

Donald S. Clark,  
Secretary.

[FR Doc. 93-15550 Filed 6-30-93; 8:45 am]

BILLING CODE 8750-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Health Service

#### Recommendations for Anabolic Steroids Under Section 1903 of the Anabolic Steroids Control Act of 1990; Delegation of Authority

Notice is hereby given that I have delegated to the Assistant Secretary for Health, with authority to redelegate, the authority vested in the Secretary of Health and Human Services under section 1903(a) of the Anabolic Steroids Control Act of 1990, title XIX of Public Law 101-647, as amended hereafter. This delegation excludes the authority to submit reports to Congress.

This delegation became effective upon the date of signature. In addition, I have affirmed and ratified any actions taken by the Assistant Secretary for Health or his subordinates which, in effect, involved the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: June 22, 1993.

Donna E. Shalala,  
Secretary.

[FR Doc. 93-15604 Filed 6-30-93; 8:45 am]

BILLING CODE 4160-01-M

#### Comprehensive Drug Abuse Prevention and Control Act of 1970, Public Law 91-513, As Amended; Delegation of Authority

Notice is hereby given that I have delegated to the Assistant Secretary for Health, with authority to redelegate, the authority to perform the functions for which the Secretary of Health and Human Services is responsible under the Comprehensive Drug Abuse Prevention and Control Act of 1970, Public Law 91-513, as amended hereafter. This delegation excludes the authority to submit reports to Congress.

This delegation supersedes the November 28, 1972 delegation from the Secretary to the Assistant Secretary for Health and Scientific Affairs for the Comprehensive Drug Abuse Prevention and Control Act of 1970, Public Law 91-513, as amended. This delegation became effective upon the date of signature. In addition, I have affirmed and ratified any actions taken by the Assistant Secretary for Health or his subordinates which, in effect, involved the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: June 22, 1993.

Donna E. Shalala,  
Secretary.

[FR Doc. 93-15603 Filed 6-30-93; 8:45 am]

BILLING CODE 4160-01-M

#### Food and Drug Administration

[Docket No. 93M-0004]

#### Tosoh Medics, Inc.; Premarket Approval of AIA-PACK AFP

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its approval of the application by Tosoh Medics, Inc., South San Francisco, CA, for premarket approval, under section 515 of the Federal Food, Drug, and Cosmetic Act (the act), of AIA-PACK AFP. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of December 18, 1992, of the approval of the application.

**DATES:** Petitions for administrative review by August 2, 1993.

**ADDRESSES:** Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

#### FOR FURTHER INFORMATION CONTACT:

Peter E. Maxim, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD 20857, 301-427-1034.

**SUPPLEMENTARY INFORMATION:** On September 27, 1991, Tosoh Medics, Inc., South San Francisco, CA 94080, submitted to CDRH an application for premarket approval of AIA-PACK AFP. The device is an immunoenzymometric assay and is indicated for the quantitative measurement of alpha-fetoprotein (AFP) in serum to aid in the management of patients with nonseminomatous testicular carcinoma.

In accordance with the provisions of section 515(c)(2) of the act (21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of 1990, this PMA was not referred to the Immunology Devices Panel, an FDA advisory panel, for review and recommendation because the information in the PMA substantially duplicates information previously reviewed by this panel. On December 18, 1992, CDRH approved the application by a letter to the applicant from the Acting Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

#### Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33 (b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a

notice of its decision in the **Federal Register**. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before August 2, 1993, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: June 21, 1993.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 93-15555 Filed 6-30-93; 8:45 am]

BILLING CODE 4160-01-F

#### Substance Abuse and Mental Health Services Administration

#### Cooperative Agreement With the Metropolitan Washington Council of Governments (COG)

**AGENCY:** Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

**ACTION:** Notice of intent to award a sole source, cost shared, demonstration cooperative agreement to support development of a model comprehensive substance abuse treatment program for the National Capital area.

**SUMMARY:** The Center for Substance Abuse Treatment (CSAT), SAMHSA, is publishing this notice to provide information to the public regarding a planned sole source, cost shared, cooperative agreement award to the Metropolitan Washington Council of Governments (COG) for the development and implementation of a model substance abuse treatment demonstration program. The project period is presently anticipated to be three years long. The first year will be funded with approximately \$2,700,000 in Federal funds and approximately \$1,350,000 in non-Federal cost sharing. This is not a request for applications. The cooperative agreement will only be

made to the Metropolitan Washington Council of Governments.

**AUTHORITY:** The award will be made under the authority of section 571 of the Public Health Service (PHS) Act. That section requires the Secretary of Health and Human Services (HHS) to fund the establishment of a model comprehensive substance abuse treatment demonstration program in the National Capital Area. The National Capital Area, as defined in the legislation, includes the District of Columbia; the counties of Arlington and Fairfax in Virginia; the cities of Alexandria, Falls Church, and Fairfax in Virginia; and (d) the counties of Montgomery and Prince George's in Maryland (and the political subdivisions located in those counties). The authority to administer this program has been delegated to the Director, CSAT.

It is CSAT's best judgement that the award should be made on a sole source basis to COG since only COG is capable of fully satisfying the eligibility and performance requirements included in section 571 of the PHS Act. The statute limits eligibility to "an organization of the general-purpose local governments within the national capital area, or another public or nonprofit private entity, and the applicant submits to the Secretary assurances satisfactory to the Secretary that, with respect to the communities in which services will be offered, the local governments of the communities will participate in the program." The COG is both the only organization of general-purpose local governments for Metropolitan Washington (as defined in the law) and the only organization that can provide reasonable assurance of the participation of all the affected local governments. The statute requires a substantial level of non-Federal contributions: the applicant for the grant must agree, with respect to the costs to be incurred by the applicant in implementing the project, to make available (directly or through donations from public or private entities) non-Federal contributions toward such costs in an amount equal to not less than \$1 for each \$2 of Federal funds provided. Accordingly, the recipient must be able to document the ability to contribute approximately \$1,350,000 in cash or in kind in the first year alone.

CSAT believes it is implicit that the recipient of the funds must be an organization currently accepted as capable of truly representing the governmental interests of all the local jurisdictions in the Washington metropolitan area. Further, it is CSAT's

best judgement that to succeed, the new program must receive wide support from government agencies dealing with addiction treatment. Again, COG is the only existing entity that satisfies the above requirements.

**BACKGROUND:** COG is the recognized regional planning organization for the Metropolitan Washington area. The organization has a long history of administering and coordinating complex projects supported by Federal funds, including several prior DHHS demonstration grants. COG serves as the Title X Family planning grant recipient for the District of Columbia (the only "State" that is a member) administering and coordinating services delivered by six delegate agencies. COG is the Federally designated Metropolitan Planning Organization for developing and implementing an area-wide regional transportation planning program. COG serves as the convener of committees in human services areas in addition to substance abuse that deal with inter-jurisdictional concerns (e.g., juvenile justice).

COG has a Drug Intervention, Treatment and Rehabilitation Committee that is comprised of the local government substance abuse administrators in the COG member jurisdictions. This committee has been very active in discussing inter-jurisdictional cooperation and has engaged in preliminary planning for joint programs. Their deliberations have been brought to the attention of the Congress and considered in the development of the authorizing statute. None of the units of State or local government are seen as appropriate, because of their limited geopolitical responsibilities and connections to a specific, sometimes limited systems of care and reimbursement. Nor is there a non-governmental treatment provider or any other planning or umbrella agency with authority, experience, or acceptability comparable to COG.

Each jurisdiction contains a variety of alcohol and drug abuse treatment programs. However, each jurisdiction does not necessarily include each type of treatment program. There is little existing inter-State planning of the extensive nature contemplated in the law, although a few of the jurisdictions do purchase specific services (for example, medical detoxification) from providers in neighboring jurisdictions, and several providers operate programs in more than one (but not all) of the affected jurisdictions.

We also note that during the recent period of cutbacks in funds available for substance abuse treatment in the three